Get the Stockscreener App
2.42
0.41%
0.010
After Hours:
2.38
-0.04
-1.65%
Cellectar Biosciences Inc stock is traded at $2.42, with a volume of 25,563.
It is up +0.41% in the last 24 hours and down -3.97% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$2.41
Open:
$2.42
24h Volume:
25,563
Relative Volume:
0.03
Market Cap:
$19.34M
Revenue:
-
Net Income/Loss:
$-20.84M
P/E Ratio:
-0.3282
EPS:
-7.3739
Net Cash Flow:
$-18.59M
1W Performance:
-3.97%
1M Performance:
-3.97%
6M Performance:
-31.64%
1Y Performance:
-52.46%
1-Day Range:
$2.35
$2.51
1-Week Range:
$2.35
$2.63
52-Week Range:
$2.20
$6.52
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
2.42 | 19.26M | 0 | -20.84M | -18.59M | -7.3739 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Upgrade | Maxim Group | Hold → Buy |
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
View All
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences Inc (CLRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cellectar Biosciences Inc (CLRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CLRB|Cellectar Biosciences Inc|Price:2.410|Chg%:-0.060 - TradingKey
Cellectar Biosciences Inc (CLRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits
Cellectar Biosciences (CLRB) Q1 2026 earnings summary - Quartr
Cellectar Biosciences (CLRB) Proxy filing Summary - Quartr
Cellectar Biosciences (CLRB) Q4 2025 earnings summary - Quartr
Cellectar Biosciences (CLRB) Registration filing Summary - Quartr
Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia - Bitget
Cellectar Publishes Phase 1 Iopofosine Data - t.co
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers - Sahm
Cellectar publishes phase 1 data on multiple myeloma treatment By Investing.com - Investing.com South Africa
Cellectar Biosciences (CLRB) Announces Positive Phase 1 Study Re - GuruFocus
Cellectar publishes phase 1 data on multiple myeloma treatment - Investing.com
Cellectar Biosciences Announces Publication of Phase 1 Data for Iopofosine I 131 in Relapsed/Refractory Multiple Myeloma - Quiver Quantitative
Cellectar Myeloma Data: 84.6% of 26 Evaluable Patients Stable or Better - Stock Titan
Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk - Yahoo Finance
Form 4 Cellectar Biosciences Inc For: 10 July By Investing.com - Investing.com Nigeria
Form 4 Cellectar Biosciences Inc For: 10 July - Investing.com India
Cellectar Biosciences, Inc. Files Form 8-K: Updated Stock Incentive Plan and Corporate Details for 2026 - Minichart
Cellectar Biosciences (NASDAQ: CLRB) awards 15,000 stock options to consultant - Stock Titan
Cellectar Biosciences (NASDAQ: CLRB) holders approve more stock awards and large warrant exercise - Stock Titan
Form 4 Cellectar Biosciences Inc For: 8 July By Investing.com - Investing.com Nigeria
Cellectar Biosciences (CLRB) CEO awarded 250,000 stock options - Stock Titan
Cellectar (CLRB) awards director Andrew Gu 25,000 options - Stock Titan
Consultant for Cellectar (NASDAQ: CLRB) receives grant of 15,000 stock options - Stock Titan
Cellectar Biosciences (CLRB) Edges Lower Amid Support Test; Resistance Holds as Range TightensMcClellan Summation - dars.gov.et
CLRBCellectar Biosciences Inc Options - Finviz
Price to book forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Enterprise value to EBIT forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Price to earnings forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Enterprise value to EBITDA forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Cellectar Biosciences, Inc. Actuals & Estimates (NASDAQ:CLRB) - TradingView
Enterprise value to revenue forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
CLRB Forecast — Price Target — Prediction for 2027 - TradingView
Cellectar Biosciences (CLRB) Surges 12.5%: Key Levels and Technical OutlookRevenue Growth Stocks - dars.gov.et
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Cellectar Biosciences Inc (CLRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cellectar Biosciences Inc (CLRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cellectar Biosciences Inc (CLRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cellectar Biosciences Inc (CLRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cellectar Biosciences Inc (CLRB) Institutional Confidence - TradingKey
Cellectar Biosciences (CLRB) Edges Higher: Consolidation Near Key ResistanceFund Manager Survey - newsline.com
Cellectar Biosciences Inc (CLRB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cellectar Biosciences (CLRB) Slides 4.27% as Support Test LoomsInstitutional Flow Picks - dars.gov.et
Number of shareholders of Cellectar Biosciences, Inc. – MUN:NV40 - TradingView
Cellectar Biosciences (CLRB) director Andrew Gu submits initial Form 3 ownership filing - Stock Titan
Cellectar Biosciences (CLRB) Declines 3.09% as Stock Tests Support Near $2.38Swing Entry Signals - newsline.com
Janus Henderson Group holds 9.99% of Cellectar Biosciences (CLRB) - Stock Titan
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):